STOCKHOLM, SE / ACCESSWIRE / January 12, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical firm that develops a broad portfolio of small molecule candidate medicine for illnesses affecting the central nervous system, with initiatives in each Alzheimer’s illness and ache, right this moment introduced that the corporate arranges a digital Capital Markets Day on 18 January 2022 at 13:00-14:30 CET, with Professor Bengt Winblad at Karolinska Institutet, Stockholm, invited as visitor presenter.
The purpose of the day is to current the event and main medical wants in AlzeCure’s analysis areas Alzheimer’s illness and neuropathic ache, in addition to present an replace on the corporate’s improvement initiatives. The presentation is adopted by a moderator-led query time the place it’s attainable to submit questions.
The Capital Markets Day doesn’t require pre-registration and may be adopted through https://www.finwire.television/webcast/alzecure-pharma/kapitalmarknadsdag/ .
The shows shall be held in Swedish. The Capital Markets Day may also be out there afterwards on AlzeCure’s web site https://www.alzecurepharma.se/en/presentations-and-interviews/ .
13:00 Alzheimer’s illness, medical wants & therapy – Professor Bengt Winblad, Karolinska Institutet
13:20 Replace on AlzeCure’s initiatives in Alzheimer’s – Johan Sandin, CSO
13:35 Neuropathic ache, medical wants & therapy – Assoc. Professor Märta Segerdal, CMO
13:50 Replace on AlzeCure’s initiatives in neuropathic ache – Johan Sandin, CSO
14:00 AlzeCure’s objectives for 2022 – Martin Jönsson, CEO
14:10 Panel dialogue & Q&A led by Kristofer Berggren, FinWire
14:25 Closing speech – Martin Jönsson, CEO
For extra info, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical firm that develops new progressive drug therapies for the therapy of extreme illnesses and situations that have an effect on the central nervous system, comparable to Alzheimer’s illness and ache – indications for which at the moment out there therapy may be very restricted. The corporate is listed on Nasdaq First North Premier Progress Market and is creating a number of parallel drug candidates primarily based on three analysis platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates the place the distinctive mechanism of motion permits for a number of indications, together with Alzheimer’s illness, in addition to cognitive issues related to traumatic mind damage, sleep apnea and Parkinson’s illness. The Alzstatin platform focuses on creating disease-modifying and preventive drug candidates for early therapy of Alzheimer’s illness and includes two drug candidates. Painless is the corporate’s analysis platform within the area of ache and incorporates two initiatives: ACD440, which is a drug candidate within the scientific improvement section for the therapy of neuropathic ache, and TrkA-NAM, which targets extreme ache in situations comparable to osteoarthritis. AlzeCure goals to pursue its personal initiatives by way of preclinical analysis and improvement by way of an early scientific section, and is regularly engaged on enterprise improvement to seek out appropriate outlicensing options with different pharmaceutical firms.
FNCA Sweden AB, +46(0)8 528 00 399 [email protected] , is the corporate’s Licensed Adviser. For extra info, please go to www.alzecurepharma.se .
AlzeCure holds a digital Capital Markets Day on 18 January
SOURCE: AlzeCure Pharma
View supply model on accesswire.com: